Your trusted source for investing success

Tag: vaccine

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Dynavax’s Hepatitis B Vaccine Recommended by CDC Advisory Committee

Dynavax Technologies (NASDAQ:DVAX) announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was approved by the U.S. Food and Drug

What Is In-Licensing?

What Is In-Licensing?

Licensing deals might be pharma’s preferred mode of business development these days—perhaps even more so than outright acquisitions.

Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results

Genocea Biosciences (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2017 and recent corporate developments.

As quoted in the press release:
“We’ve had a productive start to 2018 and are encouraged by both the progress with our lead neoantigen

Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine

Bavarian Nordic (OTC:BVNRY) announced positive results from a Phase 3 pivotal study of its investigational, non-replicating smallpox vaccine, IMVAMUNE. The study achieved both of its primary endpoints, demonstrating IMVAMUNE’s efficacy in comparison to ACAM2000, the current U.S. licensed replicating smallpox vaccine.

As quoted in the press release:
“The success of this study

BioCure Unaware of Any Material Change

BioCure Unaware of Any Material Change

Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the “Company” or “Biocure) At the request of IIROC, Biocure wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology company, announced the publication of a preclinical study using magnetic resource imaging (MRI) to follow cancer peptide uptake in tumor models, and to correlate this immune activation to the resulting anti-cancer T cell activity.

As quoted in the press release:
The Journal of Biomedical Science study, titled “Unique

Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients

Astellas Pharma (TSE:4503) and Vical (NASDAQ:VICL) announced that ASP0113, an investigational DNA vaccine being developed for cytomegalovirus-seropositive hematopoietic stem cell transplant recipients, did not meet its primary or secondary endpoints in the Phase 3 HELIOS clinical trial. The vaccine was generally well tolerated, with injection-site reactions being the most commonly reported

Tonix Pharmaceuticals Announces Publication Reporting a Potential Smallpox-Preventing Vaccine Candidate

Tonix Pharmaceuticals (Nasdaq:TNXP) a company developing innovative pharmaceutical and biological products to address major public health challenges, announced the publication of research describing the successful synthesis and characterization of a potential smallpox-preventing vaccine based on horsepox virus.

As quoted in the press release:
The peer-reviewed article, “Construction of an infectious horsepox virus

Biotech Stocks in 2018


Find out how the market will look this year


Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Dynavax’s Hepatitis B Vaccine Recommended by CDC Advisory Committee

URL: https://investingnews.com/daily/life-science-investing/biotech-investing/dynavaxs-hepatitis-b-vaccine-recommended-cdc-advisory-committee/